Welcome to our dedicated page for Milestone Scient SEC filings (Ticker: MLSS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Wondering how Milestone Scientific turns its patented computer-controlled injection technology into revenue? Start your research here. Investors who follow FDA milestones, cash runway, or royalty streams often begin with the Milestone Scientific annual report 10-K simplified and the Milestone Scientific quarterly earnings report 10-Q filing. Stock Titan’s AI instantly extracts critical details—device approval timelines, R&D spend, and global distribution stats—so you can focus on decisions, not page counts.
Need real-time alerts? Our platform streams every Milestone Scientific Form 4 insider transactions real-time, letting you track executive buys and sells as they hit EDGAR. You’ll also find the full archive of Milestone Scientific insider trading Form 4 transactions, Milestone Scientific proxy statement executive compensation, and each Milestone Scientific 8-K material events explained in plain English. AI-powered summaries highlight why a clinical-study update or distribution agreement matters, putting complex language into context for busy professionals.
Whether you’re comparing segment revenue trends, monitoring dilution risk, or simply understanding Milestone Scientific SEC documents with AI, Stock Titan offers complete coverage. Dive into Milestone Scientific earnings report filing analysis, export tables, or set custom alerts—everything you need from a single dashboard. No more hunting across multiple sites; all MLSS filings are organized, searchable, and updated the moment they post.
Milestone Scientific (NYSE:MLSS) filed a routine Form 4 reporting two small open-market sales by 10 % owner BP4 S.r.l. The insider sold 10,056 shares on 06/16/2025 at $0.8951 and 1,693 shares on 06/18/2025 at $0.88, totaling 11,749 shares (≈ $10.5 K).
Following the transactions, BP4 S.r.l.’s beneficial ownership declined by less than 0.2 % to 9,447,183 common shares. No derivative trades or additional material changes were disclosed.